ASX Healthcare Weekly: Capital Raisings, FDA Wins and Trial Moves Drive Trading

Dimerix (ASX:DXB) was the week’s biggest mover by distance, falling 43.42%. The company said its Phase 3 kidney disease trial still has more than 90% power to detect a proteinuria effect, which in plain English means management believes the study is still large enough to spot a real treatment benefit if one exists. Even so, investors sold hard. That sort of move often tells you the market wanted stronger news, such as a clear clinical win or funding certainty. At the other end, TrivarX (ASX:TRI) climbed 31.25% after appointing a new chief executive to push its brain imaging program into human trials, while LTR Pharma (ASX:LTP) rose 30.77% as investors backed its fast-acting erectile dysfunction spray after fresh prescription, trial and US entry updates.

Capital remained the lifeblood

Several names drew attention because they raised cash to keep trials moving. 4DMedical (ASX:4DX) secured $233 million across two institutional placements, even as its shares fell 15.55% for the week. Investors often like a stronger balance sheet, but they can still mark a stock down if the raise is large or if they worry existing holders were diluted. Paradigm Biopharma (ASX:PAR) dropped 28.89% despite lifting a placement and share purchase plan that should leave it with about $45 million to fund its knee osteoarthritis trial through an interim look at the data in the third quarter of 2026. Botanix Pharmaceuticals (ASX:BOT) slid 18.18% after reporting prescription growth for Sofdra but weaker net revenue because insurance deductibles reset at the start of the year. It also completed a $45 million raising and reworked supply terms to delay payments.

Regulatory wins kept opening doors

Healthcare shares also moved on government clearances, because these can decide whether a product can be sold. Acrux (ASX:ACR) gained 9.09% as it pitched a female testosterone treatment for low sexual desire in women and pointed to a large US market. Cambium Bio (ASX:CMB) said the FDA agreed to a single pivotal Phase 3 trial for Elate Ocular, which means one main late-stage study may be enough for approval if it succeeds. Nexsen (ASX:NXN) rose 8.11% after the FDA confirmed a 510(k) route for StrepSure, a simpler approval process used when a new device can be compared with an existing one. Alterity (ASX:ATH) added 5.00% after getting FDA support on manufacturing plans for its Multiple System Atrophy drug, while Anteris Technologies (ASX:AVR) rose 7.24% on US Medicare reimbursement support for its heart valve trial.

Sales growth mattered more in devices and diagnostics

Outside pure biotech, investors had real numbers to judge. Resmed (ASX:RMD) posted 11% revenue growth to US$1.43 billion, stronger margins and a 21% lift in non-GAAP earnings per share, yet still fell 6.99% over the week. Orthocell (ASX:OCC) added 3.45% after first Canadian sales of Remplir and fresh real-world data showing an 89.7% success rate in nerve repair procedures. OncoSil Medical (ASX:OSL) rose 6.19% after dose sales jumped 60% from a year earlier. Microba Life Sciences (ASX:MAP) gained 5.56% as core testing revenue nearly doubled. Echo IQ (ASX:EIQ), however, fell 14.10% despite deploying its heart imaging software at Mount Sinai. That suggests investors wanted faster revenue conversion, not just a big hospital name.

Clinical readouts stayed the main trigger for biotech

A steady stream of trial updates kept smaller drug developers moving. Clarity Pharmaceuticals (ASX:CU6) reported its prostate cancer imaging candidate found 2.6 times as many lesions as standard care, while Chimeric Therapeutics (ASX:CHM) rose 10.00% on a 60% complete response rate in a high-risk leukaemia study. Entropy Neurodynamics (ASX:ENP) jumped 12.12% after early data in binge eating disorder showed improvement across several symptoms. AdAlta (ASX:1AD) climbed 25.00% as it shifted CAR-T manufacturing to Australia after reporting rare complete tumour clearance in mesothelioma. Yet the week also showed that good data is not always enough on its own. Several stocks opened strongly and then gave back ground, which usually means early buyers took profit or others worried the next funding step could still dilute them.

What the week said about healthcare risk

The strongest buying sat around companies with a clear near-term event and a simple story investors could follow. LTR Pharma has interim Phase II data due in the second quarter of 2026. Avecho Biotechnology (ASX:AVE) rose 9.09% after beating its recruitment target ahead of a June interim analysis for its CBD insomnia trial. Actinogen (ASX:ACW) added 4.55% after a positive interim review allowed its Alzheimer’s-linked trial to continue and after it raised $16.8 million. By contrast, names with longer waits, thin cash or unclear next steps struggled to hold gains. Cynata (ASX:CYP), Recce Pharmaceuticals (ASX:RCE) and Anatara Lifesciences (ASX:ANR) each carry important milestones, but investors will keep asking how much cash is left and when the next hard result arrives.